Opens in a new tab

Edwards Lifesciences v Meril (CFI, 4 April 2025)

Date4 April 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionInfringement Action
Registry referenceACT_597277/2023 · ORD_598588/2023
PartiesEdwards Lifesciences Corporation v. Meril GmbH, Meril Life Sciences Pvt. Ltd., Meril Italy S.r.l.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By decision of 4 April 2025 (UPC_CFI_501/2023), the Munich Local Division dismisses the preliminary objections and the counterclaim for revocation of Meril GmbH, Meril Life Sciences and Meril Italy, holds that the Myval valve and its Navigator delivery system literally infringe Edwards Lifesciences’ EP 3 669 828 (prosthetic heart valve), as maintained by the EPO Opposition Division, and grants an immediately enforceable injunction with corrective measures and an interim payment of EUR 663,000. The decision matters for its broad reading of Art. 33(1)(b) UPCA to join several group companies, its adoption of the problem-solution approach and its refusal to accept a cease-and-desist undertaking without a penalty clause.

Facts and procedure

The patent, granted on 5 May 2021, was maintained in amended form by the EPO Opposition Division. Edwards sued on 27 December 2023 over the Myval valve and the Navigator delivery system. Meril counterclaimed for revocation on 26 April 2024. The oral hearing took place on 11 February 2025.

The applicable law

On jurisdiction, the Division applies Article 33(1)(b) UPCA, which allows several defendants to be sued before the division of one of them where they have a commercial relationship and the action concerns the same infringement. On validity, it examines added matter (Art. 123(2) EPC), novelty (Art. 54 EPC), inventive step (Art. 56 EPC) and sufficiency (Art. 83 EPC), under Article 65 UPCA and Article 138 EPC.

Question

Does the UPC have jurisdiction over all defendants and acts, is the patent valid and does the Myval valve infringe it?

Decision

The main request covering the UPC territories “as of the date of the oral hearing” is inadmissible, as territories must be fixed when the claim is filed. The auxiliary request listing them is admissible. The objection concerning acts before 1 June 2023 is rejected, following the Court of Appeal’s decision of 16 January 2025. Jurisdiction over Meril Italy is upheld: “the same infringement” covers several defendants accused of infringing national designations of the same European patent by the same product, and the three group companies have a commercial relationship. On the merits, the Division holds that V-shaped leaflets are optional, that “axial” and “radial” do not require a mathematically strict orientation, and that the patent is directed to one-piece leaflets. It finds no added matter, holds claims 1 and 12 novel over Nguyen, Benichou and Jaramillo, and rejects the obviousness attacks starting from Nguyen and from Lobbi combined with Nguyen, applying the problem-solution approach. Disclosure is sufficient, the attachment of the leaflets to the frame by the tabs being implicitly disclosed. The only non-infringement argument, based on the U shape of the leaflets, falls with the construction adopted: claims 1 and 12 are literally infringed. The three companies are cumulatively liable: Meril India manufactures, Meril GmbH offers through the group website despite a disclaimer and made sales in Germany, and Meril Italy presents a risk of first infringement. The cease-and-desist statement made at the hearing, without a penalty clause and for two companies only, does not remove the risk of repetition. The public interest and proportionality defences are rejected, subject to an exemption for XL valves upon an individual physician request through Edwards’ portal. The Court orders an injunction for the UPC territory except Malta backed by a penalty of EUR 20,000 per infringement, information within three weeks, recall and destruction within one week, publication by Edwards (publication on Meril’s website being refused), damages from 5 May 2021 and an uncontested interim payment of EUR 663,000, Meril bears the costs, and the decision is immediately enforceable without security.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 24(1)(c), 32(1), 33(1)(b), 34, 56(1), 63, 64, 65, 67(1), 68, 69(1), 76(1) and 80
Rules of Procedure
Rules 19.1, 118.1, 118.2(a), 118.8, 119, 191, 352, 354.1 and 354.3
European Patent Convention
Art. 54, 56, 83, 69(1), 123(2) and 138
Case law cited
Court of Appeal, Sumi Agro v Syngenta (UPC_CoA_523/2024), Court of Appeal, 16 January 2025, Fives v REEL (UPC_CoA_30/2024), UPC_CoA_382/2024, UPC_CFI_252/2023 and UPC_CoA_182/2024, UPC_CFI_355/2023, Munich Local Division, 15 November 2024 (UPC_CFI_15/2023), parallel decision on EP 3 646 825, UPC_CFI_166/2024.

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Decisions in the same proceedings

Going further

Lexicon: Patent infringement action.

Publications by Matthieu Dhenne: Pleading the Long Arm: What a UPC Statement of Claim Must Carry Beyond Jurisdiction (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

Contents of the record

Nature of the act
Infringement Action
Outcome (Dhenne Avocats summary)
La division locale de Munich rejette les exceptions préliminaires et la demande reconventionnelle en nullité, retient la contrefaçon littérale du brevet EP 3 669 828 par la valve Myval et ordonne interdiction, rappel, destruction, information et une provision de 663 000 euros, avec exemption pour les valves XL.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 3 669 828
Prosthetic heart valve
recorded proprietor: Edwards Lifesciences Corp
Patent at issue according to the summary or official headnote
Also mentioned in 11 other decision(s): Edwards Lifesciences v Meril (CFI, 12 August 2026) · Edwards Lifesciences v Meril (CFI, 26 June 2026) · Edwards Lifesciences v Meril (CFI, 17 October 2025) · Edwards Lifesciences v Meril (CFI, 3 June 2025) · Edwards Lifesciences v Meril (CFI, 14 April 2025) · Edwards Lifesciences v Meril (CFI, ORD_60824/2024, 9 April 2025) · Edwards Lifesciences v Meril (CFI, 5 February 2025) · Edwards Lifesciences v Meril (CFI, 20 December 2024)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: summary of the decision, Dhenne Avocats analysis
EP 3 646 825
A system comprising a prosthetic valve and a delivery catheter
recorded proprietor: Edwards Lifesciences Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 32 other decision(s): Edwards Lifesciences v Meril Life Sciences (CFI, 15 November 2024) · Meril Italy v Edwards Lifesciences (CFI, 19 July 2024) · Meril v Edwards Lifesciences (CFI, 19 July 2024) · Meril Italy v Edwards Lifesciences (CoA, 25 November 2025) · Edwards Lifesciences v Sintec (CFI, 5 September 2025) · Meril Italy v SWAT Medical (CoA, 5 May 2025) · Meril v SWAT Medical (CoA, 5 May 2025) · Meril Life Sciences v SWAT Medical (CoA, 5 May 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.